By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Eiger Biopharma 



Palo Alto  California    U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS



Segment
Start Up





Company News
Eiger Biopharma Completes $25 Million Debt Financing With Oxford Finance 1/4/2017 8:41:13 AM
Eiger Biopharma Announces First Patient Dosed In Open-Label Extension Of Phase 2 LIBERTY Study Of Ubenimex In Pulmonary Arterial Hypertension (PAH) 1/3/2017 6:44:47 AM
Eiger Biopharma Announces Multiple Advances In Exendin 9-39 Program For The Treatment Of Post-Bariatric Hypoglycemia (PBH) 12/12/2016 7:06:19 AM
Eiger Biopharma Updates Progress In Clinical Development Program For Exendin 9-39 To Treat Post-Bariatric Hypoglycemia (PBH) 11/29/2016 6:50:54 AM
Eiger Biopharma Announces Additional LOWR HDV Program Data, Clinical And Regulatory Plans At The American Association for Study of Liver Diseases Meeting 11/15/2016 7:29:10 AM
Eiger Biopharma Announces Positive Phase 2 Data At The American Association for Study of Liver Diseases Meeting: Multiple Paths Forward Identified With Lonafarnib Therapy In LOWR HDV Program 11/14/2016 6:46:53 AM
Eiger Biopharma Reports Third Quarter 2016 Financial Results 11/9/2016 11:54:43 AM
Eiger Biopharma Announces First Patient Dosed In Phase 2 Study Of Pegylated Interferon Lambda In Hepatitis D Virus (HDV) Infection 10/19/2016 6:52:36 AM
Eiger Biopharma Announces Orphan Designation Of Exendin 9-39 For Treatment Of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) From EMA 10/17/2016 8:28:03 AM
Eiger Biopharma Announces Abstracts And Presentations Of LOWR HDV Program At The American Association for Study of Liver Diseases Meeting 10/13/2016 9:00:20 AM
123456
//-->